Biotech startups in China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
| Drug Farm | Shanghai | Series D | $55.0M | 2026-07-13 |
| Tianhu Technology | Minhang | Series A | $29.0M | 2026-07-13 |
| Degron Therapeutics | Shanghai | Series A | $40.0M | 2026-05-14 |
| Weikaier Pharmaceutical Technology | Nanjing | Series C | $29.6M | 2026-06-02 |
| MindRank AI | Shanghai | Series B | $52.0M | 2026-07-08 |
| Bowang Pharmaceutical | Jiading | Series A | $41.0M | 2023-11-01 |
8 rows of the CSV in 5 of its 18 columns.
- The 1,440 biotech startups in China have raised $32.0B in total.
- 285 of them closed their most recent round in the last 12 months, $5.5B combined.
- The largest of those rounds is Anew Labs' $290.0M Series A, dated September 2026.
- The most recent is Huasaiboman Medical Cell Biology's $30.0M Series B on 9 November 2026.
- Qiming Venture Partners is an investor in 17 of them, more than any other fund.
- Health care is the most common other sector, with 1,203 companies (84%).
- 34% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (41% of companies with a recorded size).
- 4 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 1,440| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| Tushen Zhihe | Tushen Zhihe provides artificial intelligence protein design services. | Artificial intelligence | Minhang | Seed | $1.4M | 2026-11-09 | $1.5M | Wuxi Capital, CHENGMEI VENTURES | 11 to 50 | 2023 |
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| QL Biopharma | QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. | Biotech | Beijing | Series C | $44.7M | 2026-09-14 | $173.7M | Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 | 101 to 250 | 2018 |
| Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Hongxin Biology | Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. | Biotech | Shenzhen | Series B | $14.0M | 2026-08-13 | $14.0M | Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group | 11 to 50 | 2021 |
| Phil Rivers Technology | Phil Rivers Technology provides AI solutions for pharmaceutical research and development. | Artificial intelligence | Beijing | Series A | $29.6M | 2026-08-05 | $57.3M | Insight Capital | 51 to 100 | 2015 |
| Layerwave Bio | Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. | Biotech | Daxing | Series B | $13.8M | 2026-07-28 | $13.8M | IDG Capital, Addor Capital, Hotung Venture Capital | 51 to 100 | 2020 |
| Diyingjia Technology | Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. | Artificial intelligence | Beijing | Series C | $3.0M | 2026-07-28 | $32.3M | IDG Capital, Legend Capital, Microsoft Accelerator | 11 to 50 | 2017 |
| Shengqiang Technology | Shengqiang Technology researches, manufactures, and sells high-tech products. | Biotech | Shenzhen | Series C | $13.7M | 2026-07-26 | $13.7M | SDIC Venture Capital | 101 to 250 | 2013 |
| Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Shanghai | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
| Tianhu Technology | Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. | Artificial intelligence | Minhang | Series A | $29.0M | 2026-07-13 | $54.2M | Qiming Venture Partners, GSR United Capital, 3E Bioventures | 11 to 50 | 2021 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| SynMetaBio | SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. | Biotech | Shanghai | Series A | $14.7M | 2026-07-06 | $16.1M | MiraclePlus, Linear Capital, Danen Capital | 11 to 50 | 2021 |
| Prime Lifescience | Prime Lifescience develops a big data platform for life sciences research and analysis. | Biotech | Hangzhou | Series A | $14.7M | 2026-06-30 | $44.5M | Qiming Venture Partners, Qiji Investment, Ennovation Ventures | 11 to 50 | 2021 |
| Lingtai Krypton Biotechnology | Lingtai Krypton Biotechnology develops lncRNA drugs to treat human diseases. | Biotech | Shuangliu | Series A | $13.7M | 2026-06-26 | $13.7M | Legend Capital, Guosheng Capital, Firefly Haoyue | 11 to 50 | 2021 |
| Artivila Therapeutics | Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. | Artificial intelligence | Shenzhen | Series A | $14.7M | 2026-06-23 | $53.3M | Highlight Capital, Med-Fine Capital, Hike Capital +2 | 11 to 50 | 2018 |
| MoleculeMind | MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. | Artificial intelligence | Haidian | Series A | $86.0M | 2026-06-17 | $114.6M | Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital | 51 to 100 | 2022 |
| ThunderBio Innovation | ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. | Biotech | Jiaxing | Series B | $17.7M | 2026-06-15 | $34.6M | Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi | 11 to 50 | 2018 |
| Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Nanjing | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| Vivolight | Vivolight conducts medical research and develops intravascular interventional imaging technology. | Biotech | Nanshanqu | Series E | $13.9M | 2026-06-01 | $52.2M | CAS Star, TusStar | 51 to 100 | 2012 |
| YolTech Therapeutics | YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. | Biotech | Minhang | Series C | $73.8M | 2026-05-29 | $144.9M | K2VC, UnityVC, Decheng Capital +1 | 11 to 50 | 2021 |
| Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Shanghai | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Shanghai | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
Table 1. Biotech startups in China: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,440.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Shanghai | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| 2 | New Radiomedicine Technology | New Radiomedicine Technology supplies medical isotopes in China. | Biotech | Chengdu | Series E | $145.4M | 2026-04-03 | $330.6M | Chengdu Science and Technology Venture Capital | 101 to 250 | 2016 |
| 3 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 4 | DP Technology | DP Technology applies AI to scientific research and industrial R&D challenges worldwide. | Artificial intelligence | Haidian | Series C | $113.9M | 2025-12-24 | $253.7M | Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 | 101 to 250 | 2018 |
| 5 | Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Shanghai | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| 6 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 7 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 8 | Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| 9 | Zenitar | Zenitar conducts drug research and biomedical technology industrialization. | Biotech | Chengdu | Series C | $86.0M | 2026-01-12 | $155.7M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital | 51 to 100 | 2019 |
| 10 | MoleculeMind | MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. | Artificial intelligence | Haidian | Series A | $86.0M | 2026-06-17 | $114.6M | Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital | 51 to 100 | 2022 |
Table 2. Biotech startups in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 17 | 1% | 7 | AusperBio, Tianhu Technology, Prime Lifescience |
| 2 | Legend Capital | Venture capital firm | Beijing, China | 12 | 1% | 5 | Diyingjia Technology, Delova Biotech, Lingtai Krypton Biotechnology |
| 3 | Matrix Partners China | Venture capital firm | Beijing, China | 11 | 1% | 3 | Alioth, DP Technology, D3 Bio |
| 4 | Kaitai Capital | Venture capital firm | Hangzhou, China | 10 | 1% | 2 | Bivision, Levinthal |
| 5 | BioVenture | Venture capital firm | Suzhou, China | 9 | 1% | 4 | AusperBio, Degron Therapeutics, Essentia Biosciences |
| 6 | Hillhouse Investment | Angel group | Singapore | 9 | 1% | 5 | Etern, UniXell Biotechnology, Dishi Medical |
| 7 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 8 | 1% | 2 | HemaCell, UniXell Biotechnology |
| 8 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 7 | 0% | 2 | MoleculeMind, MAXVAX |
| 9 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 7 | 0% | 1 | HemaCell |
| 10 | IDG Capital | Private equity firm | Beijing, China | 7 | 0% | 3 | Layerwave Bio, Diyingjia Technology, MAXVAX |
| 11 | Gaorong Capital | Venture capital firm | Wangjing, China | 7 | 0% | 3 | BioGeometry, Bivision, Allink Biotherapeutics |
| 12 | CMB International Capital Corporation | Investment bank | Central, Hong Kong | 6 | 0% | 1 | HemaCell |
| 13 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 6 | 0% | ||
| 14 | Puhua Capital | Venture capital firm | Hangzhou, China | 6 | 0% | 1 | Yuce Biotechnology |
| 15 | SDIC Venture Capital | Venture capital firm | Xicheng, China | 5 | 0% | 2 | Shengqiang Technology, Weikaier Pharmaceutical Technology |
Table 3. Biotech startups in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 1,203 | 84% | $28.5B |
| Software | 87 | 6% | $3.2B |
| Artificial intelligence | 65 | 5% | $2.3B |
| Hardware | 33 | 2% | $107.5M |
| Energy | 10 | 1% | $885.9M |
| Cybersecurity | 5 | 0% | |
| Commerce | 4 | 0% | |
| Education | 3 | 0% | $2.9M |
| Fintech | 1 | 0% |
Table 4. Biotech startups in China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 9 | 3% | $195.9M |
| October 2026 | 16 | 6% | $146.6M |
| September 2026 | 18 | 6% | $836.5M |
| August 2026 | 24 | 8% | $503.4M |
| July 2026 | 35 | 12% | $551.0M |
| June 2026 | 19 | 7% | $333.2M |
| May 2026 | 25 | 9% | $499.4M |
| April 2026 | 14 | 5% | $375.2M |
| March 2026 | 19 | 7% | $363.2M |
| February 2026 | 17 | 6% | $214.8M |
| January 2026 | 38 | 13% | $591.2M |
| December 2025 | 38 | 13% | $715.9M |
| November 2025 | 13 | 5% | $138.6M |
Table 7. Biotech startups in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 234 | 16% | $4.6B |
| 2025 | 222 | 15% | $2.8B |
| 2024 | 178 | 12% | $1.2B |
| 2023 | 195 | 14% | $2.3B |
| 2022 | 147 | 10% | $4.1B |
| 2021 | 119 | 8% | $4.8B |
Table 8. Biotech startups in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 124 | 9% |
| 2020 to 2022 | 356 | 25% |
| 2015 to 2019 | 513 | 36% |
| 2010 to 2014 | 250 | 18% |
| Before 2010 | 172 | 12% |
Table 9. Biotech startups in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 86 | 8% |
| 11 to 50 | 454 | 41% |
| 51 to 100 | 256 | 23% |
| 101 to 250 | 173 | 15% |
| 251 to 500 | 71 | 6% |
| 501 to 1,000 | 50 | 4% |
| 1,001 to 5,000 | 23 | 2% |
| 5,001 to 10,000 | 3 | 0% |
| 10,001 or more | 2 | 0% |
Table 10. Biotech startups in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in China. On 16 November 2026 that is 1,440 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 1,440 rows: 540 have no round amount, 0 no city and 553 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in China are on the list?
- 1,440, in the file dated 16 November 2026. 285 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 1,440 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.